Shots:

• Novavax has initiated a P-III study assessing the efficacy- safety- and immunogenicity of NVX-CoV2373 vs PBO in Matrix-M in up to 10-000 individuals aged 18-84yrs. with/out relevant comorbidities- over the next 4-6wks.
• Half the participants will receive two IM injections of a vaccine comprising 5µg of protein antigen with 50µg Matrix‑M adjuvant- administered 21 days apart- while half of the trial participants will receive PBO
• The 1EPs & 2EPs is the first occurrence of PCR-confirmed symptomatic COVID-19 & PCR-confirmed symptomatic mod. to sev. COVID-19 with the onset at least 7 days after second study vaccination in volunteers prior not infected with SARS-CoV-2 respectively. Novavax has continued to scale-up its manufacturing capacity- currently up to 2B annually

­ Ref: Novavax | Image: MediCircle